| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2003; 42: 83-88
© 2003 British Society for Rheumatology
Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis
Rheumatology and Rehabilitation Research Unit, University of Leeds, Leeds and
1 The Binding Site, Birmingham, UK
Objective. Expression and activation of matrix metalloproteinases such as MMP-3 (stromelysin-1) and MMP-1 (collagenase-1) are increased in patients with rheumatoid arthritis (RA). Previous negative reports of their value as predictors of joint damage may be due to the lack of a large longitudinal study of early RA patients. This study evaluated their use in assessing early untreated patients with RA and predicting subsequent joint damage.
Methods. Ninety-eight patients with early untreated RA of less than 12 months duration and 20 normal controls had baseline serum samples tested with a double-antibody enzyme-linked immunosorbent assay for each of MMP-1 and MMP-3. The subsequent changes in Larsen score (
Larsen) and Health Assessment Questionnaire (HAQ) over the first 12 months were recorded.
Results. Baseline serum levels of MMP-3 and MMP-1 correlated significantly with baseline C-reactive protein (CRP) (r=0.42 and 0.49, P<0.001), HAQ (r=0.32 and 0.30, P<0.01) and Larsen (r=0.23 and 0.32, P<0.05) respectively. Analysis of the group of patients with a normal CRP at presentation (n=21) showed correlation of the baseline MMP-3 and MMP-1 with the presence of erosive disease during the first 12 months (r=0.52 and 0.65 respectively, P<0.05). Logistic regression analysis, in the patients who were non-erosive at presentation, showed that the strongest correlation with progression in Larsen score was the baseline MMP-3 level (r=0.30, P=0.01).
Conclusions. Baseline serum MMP-1 and MMP-3 levels correlate with disease activity and predict functional and radiographic outcome in early untreated RA. They may have a particular value in predicting the progression of erosive disease in patients who are not erosive at presentation.
KEY WORDS: Early, Arthritis, Prognosis, Outcome, Collagenase, Stromelysin.
Correspondence to: P. Emery, Department of Rheumatology, University of Leeds, Leeds, UK. E-mail: p.emery{at}leeds.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. W. SYVERSEN, R. LANDEWE, D. van der HEIJDE, J. M. BATHON, M. BOERS, V. P. BYKERK, O. FITZGERALD, D. D. GLADMAN, P. GARNERO, P. GEUSENS, et al. Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers J Rheumatol, August 1, 2009; 36(8): 1769 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jia, C. Wang, Z. Shi, J. Zhao, Y. Jia, Z. Zhao-Hui, X. Li, Z. Chen, and P. Zhu Inhibitory effect of CD147/HAb18 monoclonal antibody on cartilage erosion and synovitis in the SCID mouse model for rheumatoid arthritis Rheumatology, July 1, 2009; 48(7): 721 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Montero, J. Orbe, N. Varo, O. Beloqui, J. I. Monreal, J. A. Rodriguez, J. Diez, P. Libby, and J. A. Paramo C-Reactive Protein Induces Matrix Metalloproteinase-1 and -10 in Human Endothelial Cells: Implications for Clinical and Subclinical Atherosclerosis J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1369 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Chen, K.-C. Lin, D. T. Y. Yu, C. Yang, F. Huang, H.-A. Chen, T.-H. Liang, H.-T. Liao, C.-Y. Tsai, J. C. C. Wei, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity Rheumatology, April 1, 2006; 45(4): 414 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Peake, K. Khawaja, A. Myers, D. Jones, T. E. Cawston, A. D. Rowan, and H. E. Foster Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study Rheumatology, November 1, 2005; 44(11): 1383 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Stolt, H Kallberg, I Lundberg, B Sjogren, L Klareskog, L Alfredsson, and the EIRA study group Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study Ann Rheum Dis, April 1, 2005; 64(4): 582 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vessillier, G. Adams, and Y. Chernajovsky Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3 Protein Eng. Des. Sel., December 1, 2004; 17(12): 829 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Pillinger, P. B. Rosenthal, S. N. Tolani, B. Apsel, V. Dinsell, J. Greenberg, E. S. L. Chan, P. F. Gomez, and S. B. Abramson Cyclooxygenase-2-Derived E Prostaglandins Down-Regulate Matrix Metalloproteinase-1 Expression in Fibroblast-Like Synoviocytes via Inhibition of Extracellular Signal-Regulated Kinase Activation J. Immunol., December 1, 2003; 171(11): 6080 - 6089. [Abstract] [Full Text] [PDF]
|
|